Greenwich Lifesciences Inc (GLSI)

$22.82 -0.14 (-0.61%)
Market Cap 316.17M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 54,500
Avg Vol 321,886
Day's Range N/A - N/A
Shares Out 13.86M
Stochastic %K 34%
Beta 1.53
Analysts Strong Sell
Price Target $47.50

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy...

Industry: Biotechnology
Sector: Healthcare
Phone: 832 819 3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
Alwaysdiversify
Alwaysdiversify Apr. 5 at 11:15 AM
$GLSI Pure speculation here on my part. However, it seems likely that CEO Patel's stock purchases have been quiet since mid-January due to various legal restrictions. If his buying does NOT resume within a couple of weeks after the upcoming AACR, then I believe he is sitting on more material non-public information. Why? Patel has a history of executing a series of "catch-up" buys after the AACR : April 2025: After a quiet March, he executed four separate purchases on April 4, 7, 17, and 25, totaling over 18,000 shares. April 2023: He resumed buying on April 11, 18, and 19, totaling 14,000 shares immediately around the conference dates. Note: In 2024, he made a purchase on April 1, shortly before the AACR, after a heavy buying spree in March (over 45,000 shares).
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Apr. 3 at 11:42 PM
$GLSI if we get above $500 Mio in marketcap that will open the door for more institutions to buy in. Many institutions have restrictions not to buy companies under $500 Mio or low volume. This might be the reason why the company is still relatively under the radar
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Apr. 3 at 11:40 PM
$GLSI I did some simulations with gemini were we could stand in the HR as of right now if 14 events haven´t been reached in April 2026. I think 4% is still the right recurrence rate for these patients since the company cited this at their last pr. If my enrollment ramp up assumption was correct, we should be between 0,3-0,4. Every month that passes without 14 events being reached will reduce the HR even further. Remember guys that the SC doctors most likely know the total number of recurrences in the randomized group plus the exact number of enrolled patients and the ramp up. They also have the unblinded data of the open label arm and know exactly the number of recurrences there. They also know the degree of sickness of patients and how long their life expectancy should be. If by now they estimate that in the randomized group we should see normally 17-19 events, but only have 10-11 and the numbers are similar to the open label plus phase2b trial, it is no wonder that SC is backing GLSI
0 · Reply
sidr6463
sidr6463 Apr. 3 at 6:36 PM
$GLSI We are entering the time of the year when Snehal buys. Lets see what happens this time. Also, I am interested in knowing what they do to the lock up period in the next filing.
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Apr. 3 at 12:01 AM
$GLSI another month past without 14 events. We are straight in the hot zone and every month without 14 events increases the probability of success. Can´t wait to get more info on the open label arm over time.
2 · Reply
msgbrdinfo
msgbrdinfo Apr. 2 at 11:36 PM
$GLSI Yesterday on Fox Business, FDA Director Dr Marty Makary again spoke of speeding up drug approvals. Examples are a lung cancer drug approved in 44 days vs 1 year before his changes and a multiple myeloma drug approved in 55 days. He said they are looking for amazing drugs and will expedite approvals. A breast cancer recurrence vaccine BLA approved in about a month sounds good.👍
2 · Reply
Rolltide2020
Rolltide2020 Apr. 2 at 6:35 PM
$GLSI On track for lowest volume day since early December. That's ok, we know what happened shortly after that.
0 · Reply
yft212
yft212 Apr. 2 at 3:28 PM
$GLSI Added. Up to 3750 now.
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Apr. 2 at 12:57 PM
$GLSI $ARDX I own both. I would look CLOSELY at Steering Committees. The CEO backgrounds. That’s the difference. At end of 2026 the delta will be exponential with 14 events & FdA Fast-Track. I have 4x+ in GLSI. I don’t need “good luck”.
2 · Reply
Alwaysdiversify
Alwaysdiversify Apr. 2 at 11:53 AM
$GLSI MaloneBailey is a dominant player in auditing small-cap public companies. As GLSI ramps up its Phase 3 FLAMINGO-01 trial and experiences, they likely sought a firm with high-volume experience in SEC compliance for mid-tier biotech firms. Smaller, specialized firms like MaloneBailey often provide more competitive fee structures for emerging growth companies compared to larger international networks, while still maintaining the "Big 4" level of SEC scrutiny required for Nasdaq listing.
1 · Reply
Latest News on GLSI
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Mar 19, 2026, 6:00 AM EDT - 17 days ago

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Mar 18, 2026, 6:00 AM EDT - 18 days ago

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Mar 17, 2026, 6:00 AM EDT - 19 days ago

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Mar 16, 2026, 6:00 AM EDT - 20 days ago

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Mar 3, 2026, 6:00 AM EST - 4 weeks ago

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Feb 24, 2026, 6:00 AM EST - 5 weeks ago

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Jan 27, 2026, 6:00 AM EST - 2 months ago

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Jan 22, 2026, 6:00 AM EST - 2 months ago

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

Dec 29, 2025, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Dec 22, 2025, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?

Dec 15, 2025, 11:11 AM EST - 3 months ago

Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Dec 15, 2025, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Dec 8, 2025, 6:00 AM EST - 4 months ago

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Dec 3, 2025, 6:00 AM EST - 4 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Oct 9, 2025, 6:00 AM EDT - 6 months ago

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Oct 2, 2025, 6:00 AM EDT - 6 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Sep 30, 2025, 6:00 AM EDT - 6 months ago

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Sep 18, 2025, 6:00 AM EDT - 7 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Sep 10, 2025, 6:00 AM EDT - 7 months ago

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Aug 20, 2025, 9:25 AM EDT - 8 months ago

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Aug 19, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Aug 13, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Aug 11, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Apr 2, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 27, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mar 17, 2025, 6:45 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 29, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 27, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 23, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 22, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Jan 17, 2025, 8:20 AM EST - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Jan 14, 2025, 6:15 AM EST - 1 year ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Partners with GIM in Italy

Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Corporate Events

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Jun 26, 2024, 2:05 PM EDT - 1 year ago

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 1 year ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 13, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Mar 12, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 27, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Feb 22, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Feb 14, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Nov 21, 2023, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Greenwich LifeSciences Provides Year End Update

Dec 29, 2022, 6:48 AM EST - 3 years ago

Greenwich LifeSciences Provides Year End Update

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Dec 1, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Greenwich LifeSciences: Persevering CEO And Interesting Data

Sep 6, 2022, 5:40 PM EDT - 3 years ago

Greenwich LifeSciences: Persevering CEO And Interesting Data

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Aug 11, 2022, 10:30 AM EDT - 3 years ago

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Alwaysdiversify
Alwaysdiversify Apr. 5 at 11:15 AM
$GLSI Pure speculation here on my part. However, it seems likely that CEO Patel's stock purchases have been quiet since mid-January due to various legal restrictions. If his buying does NOT resume within a couple of weeks after the upcoming AACR, then I believe he is sitting on more material non-public information. Why? Patel has a history of executing a series of "catch-up" buys after the AACR : April 2025: After a quiet March, he executed four separate purchases on April 4, 7, 17, and 25, totaling over 18,000 shares. April 2023: He resumed buying on April 11, 18, and 19, totaling 14,000 shares immediately around the conference dates. Note: In 2024, he made a purchase on April 1, shortly before the AACR, after a heavy buying spree in March (over 45,000 shares).
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Apr. 3 at 11:42 PM
$GLSI if we get above $500 Mio in marketcap that will open the door for more institutions to buy in. Many institutions have restrictions not to buy companies under $500 Mio or low volume. This might be the reason why the company is still relatively under the radar
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Apr. 3 at 11:40 PM
$GLSI I did some simulations with gemini were we could stand in the HR as of right now if 14 events haven´t been reached in April 2026. I think 4% is still the right recurrence rate for these patients since the company cited this at their last pr. If my enrollment ramp up assumption was correct, we should be between 0,3-0,4. Every month that passes without 14 events being reached will reduce the HR even further. Remember guys that the SC doctors most likely know the total number of recurrences in the randomized group plus the exact number of enrolled patients and the ramp up. They also have the unblinded data of the open label arm and know exactly the number of recurrences there. They also know the degree of sickness of patients and how long their life expectancy should be. If by now they estimate that in the randomized group we should see normally 17-19 events, but only have 10-11 and the numbers are similar to the open label plus phase2b trial, it is no wonder that SC is backing GLSI
0 · Reply
sidr6463
sidr6463 Apr. 3 at 6:36 PM
$GLSI We are entering the time of the year when Snehal buys. Lets see what happens this time. Also, I am interested in knowing what they do to the lock up period in the next filing.
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Apr. 3 at 12:01 AM
$GLSI another month past without 14 events. We are straight in the hot zone and every month without 14 events increases the probability of success. Can´t wait to get more info on the open label arm over time.
2 · Reply
msgbrdinfo
msgbrdinfo Apr. 2 at 11:36 PM
$GLSI Yesterday on Fox Business, FDA Director Dr Marty Makary again spoke of speeding up drug approvals. Examples are a lung cancer drug approved in 44 days vs 1 year before his changes and a multiple myeloma drug approved in 55 days. He said they are looking for amazing drugs and will expedite approvals. A breast cancer recurrence vaccine BLA approved in about a month sounds good.👍
2 · Reply
Rolltide2020
Rolltide2020 Apr. 2 at 6:35 PM
$GLSI On track for lowest volume day since early December. That's ok, we know what happened shortly after that.
0 · Reply
yft212
yft212 Apr. 2 at 3:28 PM
$GLSI Added. Up to 3750 now.
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Apr. 2 at 12:57 PM
$GLSI $ARDX I own both. I would look CLOSELY at Steering Committees. The CEO backgrounds. That’s the difference. At end of 2026 the delta will be exponential with 14 events & FdA Fast-Track. I have 4x+ in GLSI. I don’t need “good luck”.
2 · Reply
Alwaysdiversify
Alwaysdiversify Apr. 2 at 11:53 AM
$GLSI MaloneBailey is a dominant player in auditing small-cap public companies. As GLSI ramps up its Phase 3 FLAMINGO-01 trial and experiences, they likely sought a firm with high-volume experience in SEC compliance for mid-tier biotech firms. Smaller, specialized firms like MaloneBailey often provide more competitive fee structures for emerging growth companies compared to larger international networks, while still maintaining the "Big 4" level of SEC scrutiny required for Nasdaq listing.
1 · Reply
bernardbaruch
bernardbaruch Apr. 2 at 10:37 AM
$GLSI Company switched auditors from Russell Bedford to Malone Bailey. Audited financial statements for year ending Dec. 31 2025 are delayed. David McWilliams, audit committee chair is 82 years old. In the past 9 months he has overseen removal of the legacy auditor, onboarding the new auditor, and delaying the SEC audit beyond the expected window. Not a great look. This outlier (relatively speaking) corporate governance culture contributes to the current shareholder mix. No active managers to speak of ( maybe that changes with Q1 13-Gs) & a crowded short. NIA
1 · Reply
Freixetes
Freixetes Apr. 1 at 8:45 PM
$GLSI when are the results?
2 · Reply
Prosperity1_
Prosperity1_ Apr. 1 at 6:20 PM
$GLSI Thanks everyone for your constructive feedback. I decided to jump back in and have "a good till canceled order to purchase". I set it for $18. Quarterly/yearly filing is very expensive but still a requirement for the major exchanges. To avoid the cost, delisting to the bulletin board exchange or pink sheets is an option. Prayers for this drug to succeed and save the lives of thousands of women.
5 · Reply
alandjoyce
alandjoyce Apr. 1 at 5:21 PM
$GLSI Our Happy Week. April 17-22, 2026. Will probably be back in the 30. range just ahead of the Pow wow.
0 · Reply
Rolltide2020
Rolltide2020 Apr. 1 at 3:58 PM
$GLSI "This will be the first abstract and poster from FLAMINGO-01 with statistically significant immune response data, potentially with subgroup analysis by the most prevalent HLA types. A positive immune response is an indicator that the immune system has been activated against recurring cancer cells, potentially leading to the prevention of metastatic breast cancer and improved long term survival." This is the co-authored poster. I am excited to see results.......but any amount of logic will tell you that the results will be significant if they are presenting at AACR with entire steering committee with them.
0 · Reply
ATXAMPEREStrategies
ATXAMPEREStrategies Apr. 1 at 1:41 PM
$GLSI nice to see XBI almost back to highs. Good sign for biotech sector….
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Apr. 1 at 12:48 PM
$GLSI It’s coming.
0 · Reply
Tubular9988
Tubular9988 Apr. 1 at 12:11 PM
$GLSI its possible that the delay in filing is due to ongoing merger/acquisiton talks. parties sometimes delay filings for those reasons.
4 · Reply
Machiavellia
Machiavellia Apr. 1 at 10:17 AM
$GLSI The 10-K extension is just another example of Snehal's market awareness and chessmastership imo. - Short-term delay, procedural, not an issue - Earnings unlikely to hold anything meaningful but... markets don't always react logically/positively - The AACR will now arrive days (rather than weeks) later for the next mic drop
0 · Reply
Jack_Danielss
Jack_Danielss Apr. 1 at 6:57 AM
$GLSI https://www.cnbc.com/2026/03/31/trump-iran-war.html
0 · Reply
KINGSTOCKERS
KINGSTOCKERS Mar. 31 at 11:39 PM
$GLSI No way this is a real human 😂
2 · Reply
StarlinePalaceTrades
StarlinePalaceTrades Mar. 31 at 11:08 PM
insane call dude, Glad i jumped in early with you <3 Make sure to drop that @ElevenXProfits guy below a Follow, He finds them early before the big moves 💯🔥 my top overnight holds : $SRXH $GLSI $UMAC $HIRU
0 · Reply